{"sent_idx": "80", "frame_idx": "4", "ev": "xmlns:ns0=\"http://www.w3.org/1999/xlink\">Addition of insulin detemir further reduced A1C compared with continued metformin + liraglutide (\u22120.51% [n = 162] vs. +0.02% [n = 157], respectively; estimated treatment difference [ETD] \u22120.52 [95% CI \u22120.68 to \u22120.36]; P < 0.0001), resulting in A1C values of 7.1 and 7.5%, respectively, at week 26 (Fig.", "icos": [["1", "insulin", "metformin + liraglutide", "A1C"]], "sample": "x"}
{"sent_idx": "9", "frame_idx": "0", "ev": "At week 26, A1C decreased further, by 0.5% (from 7.6% at randomization) with insulin detemir (n = 162) versus 0.02% increase without insulin detemir (n = 157) to 7.1 and 7.5%, respectively (estimated treatment difference \u22120.52 [95% CI \u22120.68 to \u22120.36]; P < 0.0001).", "icos": [["0.999387", "insulin detemir", "continuation without insulin detemir", "A1C"], ["0.9990945", "insulin detemir", "basal insulin", "A1C"], ["0.9990945", "insulin detemir", "Basal Insulin", "A1C"], ["0.99882895", "insulin detemir", "basal insulin ( detemir )", "A1C"], ["0.9988281", "insulin detemir", "basal insulin ( insulin detemir )", "A1C"]], "sample": "c"}
{"sent_idx": "11", "frame_idx": "1", "ev": "Mean weight decreased by 3.5 kg during run-in, then by 0.16 kg with insulin detemir or 0.95 kg without insulin detemir.", "icos": [["0.9994568", "insulin detemir", "Insulin detemir", "Mean weight"], ["0.9994568", "insulin detemir", "insulin detemir", "Mean weight"], ["0.9994198", "insulin detemir", "basal insulin", "Mean weight"], ["0.9994198", "insulin detemir", "Basal Insulin", "Mean weight"], ["0.9993362", "insulin detemir", "insulin", "Mean weight"]], "sample": "c"}
{"sent_idx": "21", "frame_idx": "2", "ev": "At week 26, A1C decreased further, by 0.5% (from 7.6% at randomization) with insulin detemir (n = 162) versus 0.02% increase without insulin detemir (n = 157) to 7.1 and 7.5%, respectively (estimated treatment difference \u22120.52 [95% CI \u22120.68 to \u22120.36]; P < 0.0001).", "icos": [["0.999387", "insulin detemir", "continuation without insulin detemir", "A1C"], ["0.9990945", "insulin detemir", "basal insulin", "A1C"], ["0.9990945", "insulin detemir", "Basal Insulin", "A1C"], ["0.99882895", "insulin detemir", "basal insulin ( detemir )", "A1C"], ["0.9988281", "insulin detemir", "basal insulin ( insulin detemir )", "A1C"]], "sample": "c"}
{"sent_idx": "23", "frame_idx": "3", "ev": "Mean weight decreased by 3.5 kg during run-in, then by 0.16 kg with insulin detemir or 0.95 kg without insulin detemir.", "icos": [["0.9994568", "insulin detemir", "Insulin detemir", "Mean weight"], ["0.9994568", "insulin detemir", "insulin detemir", "Mean weight"], ["0.9994198", "insulin detemir", "basal insulin", "Mean weight"], ["0.9994198", "insulin detemir", "Basal Insulin", "Mean weight"], ["0.9993362", "insulin detemir", "insulin", "Mean weight"]], "sample": "c"}
{"sent_idx": "141", "frame_idx": "7", "ev": "In this setting, add-on exenatide with insulin optimization was associated with a 1.7% reduction in A1C levels (from a baseline of 8.3\u20136.7% vs. 1.0% A1C reduction with basal insulin optimization only), modest weight loss, and no significant increase in risk of minor hypoglycemia.", "icos": [["0.9993067", "exenatide", "basal insulin ( insulin detemir )", "risk of minor hypoglycemia ."], ["0.99923956", "exenatide", "basal insulin", "risk of minor hypoglycemia ."], ["0.99923956", "exenatide", "Basal Insulin", "risk of minor hypoglycemia ."], ["0.99921894", "exenatide", "exenatide or continuation of basal insulin only", "risk of minor hypoglycemia ."], ["0.9987104", "exenatide", "basal insulin ( detemir )", "risk of minor hypoglycemia ."]], "sample": "c"}
{"sent_idx": "141", "frame_idx": "8", "ev": "In this setting, add-on exenatide with insulin optimization was associated with a 1.7% reduction in A1C levels (from a baseline of 8.3\u20136.7% vs. 1.0% A1C reduction with basal insulin optimization only), modest weight loss, and no significant increase in risk of minor hypoglycemia.", "icos": [["0.99938357", "exenatide", "basal insulin ( insulin detemir )", "weight loss"], ["0.99935883", "exenatide", "exenatide or continuation of basal insulin only", "weight loss"], ["0.99934536", "exenatide", "basal insulin", "weight loss"], ["0.99934536", "exenatide", "Basal Insulin", "weight loss"], ["0.9991171", "exenatide", "basal insulin ( detemir )", "weight loss"]], "sample": "c"}
{"sent_idx": "141", "frame_idx": "9", "ev": "In this setting, add-on exenatide with insulin optimization was associated with a 1.7% reduction in A1C levels (from a baseline of 8.3\u20136.7% vs. 1.0% A1C reduction with basal insulin optimization only), modest weight loss, and no significant increase in risk of minor hypoglycemia.", "icos": [["0.99932456", "exenatide", "basal insulin ( insulin detemir )", "A1C levels"], ["0.9993104", "exenatide", "basal insulin", "A1C levels"], ["0.9993104", "exenatide", "Basal Insulin", "A1C levels"], ["0.9992793", "exenatide", "exenatide or continuation of basal insulin only", "A1C levels"], ["0.99858665", "exenatide", "basal insulin ( detemir )", "A1C levels"]], "sample": "c"}
